Testing a KRAS drug and doxorubicin for certain solid tumors
Treatments studied
Part of Cancer, Genetic & congenital clinical trials.
This Phase 1 study tests a drug called NEROFE together with doxorubicin in people whose tumors have a specific KRAS mutation and show ST2 in tumor tissue. It’s meant to find the safest dose and whether the treatment can shrink or control these advanced cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or metastatic solid tumor you can’t remove with surgery, and it has a KRAS mutation confirmed by a standard test (blood or tumor testing is allowed).
- Your tumor tissue must test positive for ST2 using a lab staining test (immunochemistry).
- Your cancer has gotten worse (or you couldn’t tolerate) available standard treatments, and you can have had no more than 2 prior types of systemic treatment for advanced disease.
- You must be well enough to participate: ECOG performance status 0 to 2, and blood counts and organ function must meet lab thresholds.
- Your cancer must be measurable on scans and be in a place where doctors can take repeat core needle biopsies.
- You must be able to safely get study-related blood draws, usually through a stable vein line (like a port or PICC).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
This trial tests two new drugs together for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The treatment may help shrink tumors or slow their growth.
This study tests an experimental drug (RX001) given directly into tumors for people with advanced lung cancer that has a KRAS mutation. It is a phase 1 trial, so the main goal is to check safety and find a good dose.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.